News | January 23, 2024
Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
This product has sales of about US$ 20 million in Europe
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Subscribe To Our Newsletter & Stay Updated
